Your browser doesn't support javascript.
loading
Development of a potent Zika virus vaccine using self-amplifying messenger RNA.
Luisi, Kate; Morabito, Kaitlyn M; Burgomaster, Katherine E; Sharma, Mayuri; Kong, Wing-Pui; Foreman, Bryant M; Patel, Sonal; Fisher, Brian; Aleshnick, Maya A; Laliberte, Jason; Wallace, Madison; Ruckwardt, Tracy J; Gordon, David N; Linton, Christine; Ruggiero, Nicole; Cohen, Jessica L; Johnson, Russell; Aggarwal, Kunal; Ko, Sung-Youl; Yang, Eun Sung; Pelc, Rebecca S; Dowd, Kimberly A; O'Hagan, Derek; Ulmer, Jeffrey; Mossman, Sally; Sambor, Anna; Lepine, Edith; Mascola, John R; Pierson, Theodore C; Graham, Barney S; Yu, Dong.
Affiliation
  • Luisi K; GSK Vaccines, Rockville, MD 20850, USA.
  • Morabito KM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Burgomaster KE; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Sharma M; GSK Vaccines, Rockville, MD 20850, USA.
  • Kong WP; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Foreman BM; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Patel S; GSK Vaccines, Rockville, MD 20850, USA.
  • Fisher B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Aleshnick MA; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Laliberte J; GSK Vaccines, Rockville, MD 20850, USA.
  • Wallace M; GSK Vaccines, Rockville, MD 20850, USA.
  • Ruckwardt TJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Gordon DN; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Linton C; GSK Vaccines, Rockville, MD 20850, USA.
  • Ruggiero N; GSK Vaccines, Rockville, MD 20850, USA.
  • Cohen JL; GSK Vaccines, Rockville, MD 20850, USA.
  • Johnson R; GSK Vaccines, Rockville, MD 20850, USA.
  • Aggarwal K; GSK Vaccines, Rockville, MD 20850, USA.
  • Ko SY; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Yang ES; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Pelc RS; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Dowd KA; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • O'Hagan D; GSK Vaccines, Rockville, MD 20850, USA.
  • Ulmer J; GSK Vaccines, Rockville, MD 20850, USA.
  • Mossman S; GSK Vaccines, Rockville, MD 20850, USA.
  • Sambor A; GSK Vaccines, Rockville, MD 20850, USA.
  • Lepine E; GSK Vaccines, Rockville, MD 20850, USA.
  • Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Pierson TC; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Yu D; GSK Vaccines, Rockville, MD 20850, USA.
Sci Adv ; 6(32): eaba5068, 2020 08.
Article in En | MEDLINE | ID: mdl-32821824
Zika virus (ZIKV) is the cause of a pandemic associated with microcephaly in newborns and Guillain-Barre syndrome in adults. Currently, there are no available treatments or vaccines for ZIKV, and the development of a safe and effective vaccine is a high priority for many global health organizations. We describe the development of ZIKV vaccine candidates using the self-amplifying messenger RNA (SAM) platform technology delivered by cationic nanoemulsion (CNE) that allows bedside mixing and is particularly useful for rapid responses to pandemic outbreaks. Two immunizations of either of the two lead SAM (CNE) vaccine candidates elicited potent neutralizing antibody responses to ZIKV in mice and nonhuman primates. Both SAM (CNE) vaccines protected these animals from ZIKV challenge, with one candidate providing complete protection against ZIKV infection in nonhuman primates. The data provide a preclinical proof of concept that a SAM (CNE) vaccine candidate can rapidly elicit protective immunity against ZIKV.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Viral Vaccines / Zika Virus / Zika Virus Infection Limits: Animals Language: En Journal: Sci Adv Year: 2020 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Viral Vaccines / Zika Virus / Zika Virus Infection Limits: Animals Language: En Journal: Sci Adv Year: 2020 Document type: Article Affiliation country: United States Country of publication: United States